ArticleFrontiers in nutrition2025
Burden analysis of uterine fibroids and endometriosis in reproductive-age women globally, in China, India, and the United States, 1990-2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Menopausal Hormone Therapy on Uterine Fibroids in Women During Menopausal Transition.International journal of women's health · 2026Article
- Endometriosis-Associated Infertility in China: Epidemiological Trends, Future Projection, and Real-World Clinical Insights.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine fibroids and endometriosis are common benign gynecological diseases affecting the health of women of childbearing age, characterized by high incidence and recurrence rates. Despite the increasing global emphasis on women's health, there is still a lack of systematic research on the burden these diseases impose on healthcare systems and society. This study is the first to comprehensively assess the disease burden on women of childbearing age globally, as well as in China, India, and the United States, from 1990 to 2021, and to predict future trends. Methods: Based on the Global Burden of Disease Study 2021 (GBD 2021) data, the incidence and age-standardized incidence rate (ASIR), disability-adjusted life years (DALYs), and age-standardized DALY rate (ASDR) were analyzed. Methods such as joinpoint regression, decomposition analysis, health inequality indices, and Bayesian age-period-cohort (BAPC) models were used to predict disease trends up to 2036. Results: In 2021, the global ASIR for uterine fibroids was 250.93 per 100,000 [showing an upward trend, estimated annual percentage change (EAPC) = 0.24], while the ASIR for endometriosis was 88.52 per 100,000 (showing a downward trend, EAPC = -1.00). The number of cases in China, India, and the United States accounted for nearly half of the global total. Decomposition analysis shows that population growth is the main cause of the burden of uterine fibroids, while epidemiological changes have alleviated the burden of endometriosis. The health inequality analysis indicates that the disease burden is heavier in high-Socio-Demographic Index (SDI) populations. Predictions show that by 2036, the global burden of uterine fibroids will continue to grow, while the burden of endometriosis will generally decline (except in the United States). Conclusion: The burden of uterine fibroids continues to increase, and although the burden of endometriosis has decreased, it remains severe. Targeted interventions are needed, including early screening, equitable distribution of medical resources, and country-specific strategies, to eliminate health inequalities and mitigate the long-term impact of these diseases on global women's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.